文献速递前列腺癌

前列腺癌筛查减少对分期迁移的负面影响:澳大利亚经验

Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.
PubMed 文献 · BJU Int · 2025-03-06

研究评估澳大利亚自2009年RACGP反对前列腺癌筛查后筛查率变化及其与根治性前列腺切除术(RP)时更晚期疾病的相关性。结果显示2009至2018年PSA检测率从每10万男性8470次降至4910次,17375例RP标本中非器官局限性疾病年增5.4%,PSA检测减少与非器官局限性疾病增加强相关。

要点

  • 2009至2018年新南威尔士州PSA检测率从每10万男性8470次降至4910次。
  • 17375例RP标本显示非器官局限性疾病年增5.4%,与Gleason分级无关。
  • PSA检测减少与RP时非器官局限性疾病增加强相关。

核心结论

  • 2009年RACGP反对前列腺癌筛查的指南与RP时更晚期疾病强相关,可能提示患者就诊较晚。
  • 低级别和有利中危疾病的监测增加以及高体积或高级别前列腺癌手术使用增加可能影响结果解读。

研究设计与样本

  • 回顾性分析2007至2018年澳大利亚新南威尔士州接受RP患者的组织病理学资料,数据来自Douglass Hanly Moir前瞻性维护的病理数据库。
  • PSA检测率来自Medicare Statistics数据库,人口数据来自澳大利亚卫生与福利研究所和统计局。

主要发现

  • 2009至2018年新南威尔士州PSA检测率从每10万男性8470次降至4910次,年降约5%。
  • 17375例RP患者组织病理学显示非器官局限性疾病年增5.4%,与Gleason分级无关。
  • PSA检测减少与RP时非器官局限性疾病增加呈强相关。

临床怎么用

  • 多数国际指南及澳大利亚前列腺癌基金会指南现已推荐50至69岁男性进行前列腺癌筛查。
  • 作者认为2024年最新RACGP指南更新以反映支持前列腺癌筛查的新证据值得称赞。

局限性

  • 低级别和有利中危疾病的监测使用增加可能影响结果解读。
  • 高体积或高级别前列腺癌诊断时手术使用增加可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if Australian prostate cancer screening has declined since the Royal Australasian College of General Practitioners (RACGP) recommended against prostate cancer screening in 2009 and correlate screening trends with more advanced disease at radical prostatectomy (RP) in Australia. PATIENTS AND METHODS: Histopathology of patients undergoing RP from 2007 to 2018 in the state of New South Wales (NSW), Australia was accessed from a prospectively maintained pathology database by Douglass Hanly Moir, the largest pathology provider in NSW. Prostate-specific antigen (PSA) testing rates were obtained via the Medicare Statistics database (Australian Government). Population data were obtained from the Australian Institute of Health and Welfare and Bureau of Statistics. RESULTS: Prostate-specific antigen testing decreased significantly in NSW, Australia dropping from 8470 to 4910 tests per 100 000 males from 2009 to 2018, approximately a 5% annual percentage decrease. Histopathology of 17 375 patients who underwent RP during this time showed a 5.4% annual increase in non-organ-confined disease at RP, which was irrespective of Gleason Grade. There was a strong correlation between the decrease in PSA testing with an increase in non-organ-confined disease at RP. CONCLUSIONS: In conclusion, the RACGP guidelines recommending against prostate cancer screening in 2009 correlates strongly with more advanced disease found at RP. This could indicate that patients were presenting later with more advanced disease. However, the increasing use of surveillance of low-grade and favourable intermediate-risk disease and also the potential increasing use of surgery for higher-volume or -grade prostate cancer at diagnosis could impact on the interpretation of our findings. Most international guidelines, as well as the Prostate Cancer Foundation of Australia Guidelines, have now recommended prostate cancer screening in men aged 50-69 years and it is commendable that the latest 2024 RACGP guidelines have been updated to reflect the new evidence supporting prostate cancer screening.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kam J, Chalasani V, Goolam AS, et al. Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience. BJU Int. 2025. PMID: 40051061. doi:10.1111/bju.16654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。